Nanoprobing of α-synuclein misfolding and aggregation with atomic force microscopy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 2, 2011, Pages 146-152

  Yu, Junping ^a   Warnke, Julia ^b   Lyubchenko, Yuri L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

synuclein; AFM force spectroscopy; Neurodegenerative diseases; Parkinson's disease; Protein aggregation

Indexed keywords

ACIDIC PH; AFM; ELECTROSTATIC INTERACTIONS; EXPERIMENTAL SYSTEM; FAVORABLE CONDITIONS; FORCE SPECTROSCOPY; HIGH SENSITIVITY; IN-LINE; MISFOLDING; NANO SCALE; NANO-TOOL; NEUTRAL PH; PARKINSON'S DISEASE; PROTEIN AGGREGATION; RAPID ANALYSIS; SYNUCLEIN;

AGGLOMERATION; ATOMIC FORCE MICROSCOPY; ATOMIC SPECTROSCOPY; PARKS; PH EFFECTS; POSITIVE IONS; PROTEINS;

NEURODEGENERATIVE DISEASES;

ALPHA SYNUCLEIN; ALUMINUM; DOPAMINE; ZINC;

ARTICLE; ATOMIC FORCE MICROSCOPY; CONFORMATIONAL TRANSITION; IONIC STRENGTH; NANOPROBE; NONHUMAN; PH MEASUREMENT; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; STATIC ELECTRICITY;

ALPHA-SYNUCLEIN; ALUMINUM; CATIONS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ATOMIC FORCE; NANOMEDICINE; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; STATIC ELECTRICITY; ZINC;

EID: 79952755943     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.08.001     Document Type: Article

References (24)

1. Parot P., Dufrene Y.F., Hinterdorfer P., Le Grimellec C., Navajas D., Pellequer J.L., et al. Past, present and future of atomic force microscopy in life sciences and medicine. J Mol Recognit 2007, 20:418-431.
2. Puchner E.M., Gaub H.E. Force and function: probing proteins with AFM-based force spectroscopy. Curr Opin Struct Biol 2009, 19:605-614.
3. McAllister C., Karymov M.A., Kawano Y., Lushnikov A.Y., Mikheikin A., Uversky V.N., et al. Protein interactions and misfolding analyzed by AFM force spectroscopy. J Mol Biol 2005, 354:1028-1042.
4. Kransnoslobodtsev A.V., Shlyakhtenko L.S., Ukraintsev E., Zaikova T.O., Keana J.F.W., Lyubchenko Y.L. Nanomedicine and protein misfolding diseases. Nanomedicine: NBM 2005, 1:300-305.
5. Lyubchenko Y.L., Sherman S., Shlyakhtenko L.S., Uversky V.N. Nanoimaging for protein misfolding and related diseases. J Cell Biochem 2006, 99:53-70.
6. Yu J., Malkova S., Lyubchenko Y.L. α-Synuclein misfolding: single molecule AFM force spectroscopy study. J Mol Biol 2008, 384:992-1001.
7. Yu J., Lyubchenko Y.L. Early stages for Parkinson's development: α-synuclein misfolding and aggregation. J Neuroimmune Pharmacol 2009, 4:10-16.
8. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 2001, 294:1346-1349.
9. Martin W.R., Wieler M. Treatment of Parkinson's disease. Can J Neurol Sci 2003, 30(Suppl 1):S27-S33.
10. Riederer P., Gerlach M., Muller T., Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007, 13:466-479.
11. Hoyer W., Antony T., Cherny D., Heim G., Jovin T.M., Subramaniam V. Dependence of α-synuclein aggregate morphology on solution conditions. J Mol Biol 2002, 322:383-393.
12. Hoyer W., Cherny D., Subramanian V., Jovin T.M. Impact of the acidic C-terminal region comprising amino acids 109-140 on α-synuclein aggregation in vitro. Biochemistry 2004, 43:16233-16242.
13. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001, 276:44284-44296.
14. Barnham K.J., Bush A.I. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 2008, 12:222-228.
15. Khan A., Ashcroft A.E., Higenell V., Korchazhkina O.V., Exley C. Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. J Inorg Biochem 2005, 99:1920-1927.
16. Brown D.R. Interactions between metals and α-synuclein-function or artefact?. FEBS J 2007, 274:3766-3774.
17. Kuhner F., Costa L.T., Bisch P.M., Thalhammer S., Heckl W.M., Gaub H.E. LexA-DNA bond strength by single molecule force spectroscopy. Biophys J 2004, 87:2683-2690.
18. Yu J., Wang Q., Shi X., Ma X., Yang H., Chen Y.G., et al. Single-molecule force spectroscopy study of interaction between transforming growth factor α1 and its receptor in living cells. J Phys Chem B 2007, 111:13619-13625.
19. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J Biol Chem 2001, 276:10737-10744.
20. Hashimoto M., Hsu L.J., Sisk A., Xia Y., Takeda A., Sundsmo M., et al. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 1998, 799:301-306.
21. Yamin G., Glaser C.B., Uversky V.N., Fink A.L. Certain metals trigger fibrillation of methionine-oxidized α-synuclein. J Biol Chem 2003, 278:27630-27635.
22. Kim T.D., Paik S.R., Yang C.H., Kim J. Structural changes in α-synuclein affect its chaperone-like activity in vitro. Protein Sci 2000, 9:2489-2496.
23. Paik S.R., Lee J.H., Kim D.H., Chang C.S., Kim J. Aluminum-induced structural alterations of the precursor of the non-A β component of Alzheimer's disease amyloid. Arch Biochem Biophys 1997, 344:325-334.
24. McClendon S., Rospigliosi C.C., Eliezer D. Charge neutralization and collapse of the C-terminal tail of α-synuclein at low pH. Protein Sci 2009, 18:1531-1540.